50
Participants
Start Date
June 5, 2023
Primary Completion Date
June 4, 2025
Study Completion Date
December 31, 2025
Truvada (tenofovir/emtricitabine)
Doses and route of administration of the study drug will be kept the same as for the FDA-approved indication of HIV-1 prevention in healthy individuals. The study drug is not FDA-approved for the treatment of multiple sclerosis.
Massachusetts General Hospital, Boston
Solving MS
UNKNOWN
Massachusetts General Hospital
OTHER